U.S. Markets closed

Fluidigm Corp (FLDM) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Fluidigm Corp (FLDM) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies. Fluidigm Corp has a market cap of $957.620 million; its shares were traded at around $13.81 with and P/S ratio of 4.96. Fluidigm Corp had annual average EBITDA growth of 19.90% over the past ten years.

For the last quarter Fluidigm Corp reported a revenue of $32.3 million, compared with the revenue of $27.74 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $113.0 million, an increase of 10.8% from last year. For the last five years Fluidigm Corp had an average revenue growth rate of 5.3% a year.

The reported loss per diluted share was $1.49 for the year, compared with the loss per share of $1.9 in the previous year. The Fluidigm Corp had an operating margin of -42.64%, compared with the operating margin of -57.25% a year before. The 10-year historical median operating margin of Fluidigm Corp is -45.31%. The profitability rank of the company is 5 (out of 10).

At the current stock price of $13.81, Fluidigm Corp is traded at 40.6% premium to its historical median P/S valuation band of $9.82. The P/S ratio of the stock is 4.96, while the historical median P/S ratio is 3.53. The stock gained 108.40% during the past 12 months.

For the complete 20-year historical financial data of FLDM, click here.

This article first appeared on GuruFocus.